Mostrar el registro sencillo del ítem
dc.contributor.author | Martín Carrasco, Clara | |
dc.contributor.author | Delgado Bonet, Pablo | |
dc.contributor.author | Tomeo Martín, Beatriz Davinia | |
dc.contributor.author | Pastor, Josep | |
dc.contributor.author | de la Riva, Claudia | |
dc.contributor.author | Palau Concejo, Paula | |
dc.contributor.author | del Castillo Magan, Noemi | |
dc.contributor.author | García Castro, Javier | |
dc.contributor.author | Perisé Barrios, Ana Judith | |
dc.date.accessioned | 2022-10-19T12:57:32Z | |
dc.date.available | 2022-10-19T12:57:32Z | |
dc.date.created | 2022-06-28 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12080/32720 | |
dc.description.abstract | : The use of oncolytic viruses is an innovative approach to lyse tumor cells and induce antitumor immune responses. Eight dogs diagnosed with carcinoma/adenocarcinoma were intratumorally treated with ICOCAV15, an oncolytic canine adenovirus (CAV). To evaluate the treatment¿s safety, a blood count, biochemistry, and coagulation test were performed before treatment and during follow-up. Immune populations were analyzed by flow cytometry. Anti-adenovirus antibodies were also determined. The immune infiltration, vascularization, and viral presence in the tumor were determined by CD3, CD4, CD20, CD31 and CAV by immunohistochemistry. All the dogs maintained a good quality of life during follow-up, and some had increased median survival time when compared with dogs treated with chemotherapy. No treatment-related adverse effects were detected. The Response Evaluation Criteria In Solid Tumors criteria were also assessed: two patients showed a partial response and the rest showed stable disease at various times during the study. ICOCAV15 was detected inside the tumor during follow-up, and antiviral antibodies were detected in all patients. Furthermore, the tumor-infiltrating immune cells increased after viral administration. Therefore, we suggest that intratumorally administered ICOCAV15 could represent as a new tool for the treatment of canine carcinoma because it is safe, well-tolerated by dogs, and shows promising results. Keywords: oncolytic virus; virotherapy; immunotherapy; ICOCAV15; canine carcinoma | es_ES |
dc.format | application/pdf | es_ES |
dc.language | eng | es_ES |
dc.rights | CC-BY | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.es | es_ES |
dc.title | Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | es_ES |
dc.identifier.location | N/A | es_ES |